multiple myeloma
Conditions
Interventions
therapy group:selinexor combined with bortezomib, thalidomide and dexamethasone
Sponsors
First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign the informed consent; 2. Aged between 18 (inclusive) and 75 (inclusive); 3. Patients with multiple myeloma who have received previous treatment (induction, autologous transplantation and maintenance of the same line of treatment), and who have obtained at least partial remission in the induction treatment stage, but patients with disease progression, the criteria for disease progression must meet the IMWG 2016 diagnostic and efficacy evaluation criteria; 4. Have measurable multiple myeloma; 5. No severe liver and kidney insufficiency; 6. Expected survival greater than 6 months.
Exclusion criteria
Exclusion criteria: 1. Intolerance to thalidomide and or bortezomib; 2. Patients with unstable or active cardiovascular system diseases; 3. Peripheral neuropathy of grade >=3 and painful neuropathy of grade >=2 within 3 weeks before administration; 4. Selective nuclear export inhibitors have been used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease;Progression-free survival;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactCai Zhen
Outcome results
None listed